You are here

  • Home
  • Archive
  • Volume 15, Issue 5
  • Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

Article metrics

Article menu
Download PDFPDF
Original Article
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

 

Online download statistics by month:

Online download statistics by month: February 2019 to April 2024

AbstractFullPdf
Feb 20191201
Mar 20191902
Apr 2019300
May 20192400
Jun 2019800
Jul 2019700
Aug 2019900
Sep 2019200
Oct 20191600
Nov 20191700
Dec 20191401
Jan 20201300
Feb 20201600
Mar 2020700
Apr 2020200
May 20201000
Jun 20201000
Jul 20201600
Aug 20201600
Sep 20201400
Oct 20202000
Nov 20201802
Dec 2020900
Jan 20211000
Feb 20211000
Mar 2021400
Apr 2021200
May 2021100
Jun 2021400
Jul 2021300
Aug 2021200
Sep 2021200
Oct 20212200
Nov 20211301
Dec 2021800
Jan 20223900
Feb 20221700
Mar 20224401
Apr 20222900
May 20228500
Jun 20224201
Jul 20221100
Aug 20223400
Sep 20224100
Oct 20223301
Nov 20222400
Dec 20222400
Jan 20231800
Feb 20236100
Mar 2023600
Apr 20231401
May 2023900
Jun 2023800
Jul 20231200
Aug 20232402
Sep 20231101
Oct 20231900
Nov 20231301
Dec 20232200
Jan 20241600
Feb 2024400
Mar 20241900
Apr 20241200
Total1054015